Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 555 of 6351
-
New hope for ruptured liver cancer: drug combo aims to stop recurrence
Disease control Recruiting nowPrimary liver cancer-particularly hepatocellular carcinoma (HCC)-remains a major health burden in China, characterized by high incidence and mortality rates and poor 5-year survival. Spontaneous rupture of HCC (SRHCC), although a relatively uncommon complication, is associated wi…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Poop pills may revive immunotherapy in lung cancer patients
Disease control Recruiting nowThe goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small cell lung cancer (NSCLC) following antibiotic exposure…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could less radiation be just as good for nasopharyngeal cancer?
Disease control OngoingTo evaluate the locoregional control, survival rate, toxicity, and quality of life in patients with nasopharyngeal carcinoma treated with reduced prophylactic irradiation doses to the Low-Risk Clinical Target Volume (CTV).
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug duo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pirtobrutinib, a type of…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could sharing lived experiences ease the burden of dementia care?
Symptom relief Recruiting nowThe Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing…
Sponsor: University of Nottingham • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New weekly injection could help shed pounds without diabetes
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a new skin ointment quiet psoriasis inflammation?
Disease control Recruiting nowPsoriasis is a chronic, recurrent, inflammatory, and systemic disease mediated by immunity, induced by a combination of genetic and environmental factors. Its typical clinical manifestations are scaly erythema or plaques, which may be localized or widespread. It is non-contagious…
Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new preservation fluid keep donor kidneys healthier for transplant?
Disease control Recruiting nowInsufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preserv…
Sponsor: Vivalyx GmbH • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New vaccine aims to boost immune system against advanced breast cancer
Disease control Recruiting nowThis phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contai…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Putting patients in the Driver's seat: can choice improve HIV treatment success?
Disease control Recruiting nowRepeat and prolonged treatment interruption (TI) is common and the major threat to HIV epidemic control in eastern and southern Africa. The proposed project will test an innovative long-term dynamic choice intervention for ART clients experiencing TI in Malawi. Findings will prov…
Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug duo aims to outsmart resistant breast cancer
Disease control Recruiting nowThe goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor an…
Phase 1/2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
AI reads tumor slides to forecast cancer spread
Knowledge-focused Recruiting nowThe goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer. The main question it aims to answer is: Can a multimodal AI model, trained on routinely ava…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on kidney disease in early trial
Disease control Recruiting nowA single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Early phase 1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New triple-drug attack shows promise for hard-to-treat ovarian cancer
Disease control Recruiting nowOvarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers. Because no reliable tools exist for early detection, approximately 70 % of patients are diagnosed at an advanced …
Phase 2 • Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can brain scans and gut bacteria predict suicide risk in young people?
Knowledge-focused Recruiting nowThe YOU-SURF project is at the forefront of youth suicide prevention, with the goal of integrating multimodal clinical and neurobiological data to comprehensively identify risk factors and the most effective intervention strategies. Suicide is one of the leading causes of death a…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Engineered immune cells take on deadly brain tumor
Disease control Not yet recruitingA Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Early phase 1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Peanut allergy breakthrough? new study tests daily dosing to build tolerance in kids
Disease control Recruiting nowWhile rigorous clinical trials have established peanut OIT as a promising therapy capable of inducing desensitization and even remission, its transition to routine clinical practice requires robust real-world evidence. Current management relies on strict avoidance, and the lack o…
Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo aims to outperform chemo in rare ovarian cancer
Disease control Recruiting nowThe goal of this phase 3 clinical trial is to evaluate whether QL1706 plus bevacizumab can effectively treat adult female patients (18 to \<75 years old) with newly diagnosed FIGO stage IC-IV ovarian clear cell carcinoma. The main questions it aims to answer are: 1. Does QL1706 …
Phase 3 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Art therapy vs. music: which soothes fear of childbirth?
Symptom relief CompletedThis randomized controlled trial evaluates the effects of mandala coloring and music listening on fear of childbirth among pregnant women. Participants are randomly assigned to one of three groups: a mandala coloring group, a music listening group, or a control group. The interve…
Sponsor: Osmaniye Korkut Ata University • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC